FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020291286> ?p ?o ?g. }

• W3020291286 abstract "Aim: to conduct a pharmacoeconomic analysis of chemotherapy taking into account the types of malignant neoplasms of the bronchi and lung, and to calculate pharmacoeconomic efficiency. Materials and methods . The materials for the study were the data of the Moscow Cancer Hospital n.a. D.D. Pletnev for 2019. The cost of drugs was calculated according to the data of the website aptekamos.ru (for June 2019). Results and discussion . For 300 patients with squamous non-small cell lung cancer, it is required 3205.5 courses of chemotherapy of I (1747.5) and II (1458) lines. For 200 patients with non-small cell non-squamous EGFR positive lung cancer, it is required 1,413.1 courses of chemotherapy and targeted therapy. For 70 patients with non-squamous cell non-small cell lung cancer with ALK mutation, it is required 450.2 courses of chemotherapy and targeted therapy. For 280 patients with non-squamous cell non-small cell lung cancer lung cancer without mutations, it is required 7515 chemotherapy courses. For 150 patients with small cell lung cancer, it is required 1,656.8 courses of chemotherapy. Thus, a total sample of 1000 patients, excluding the type of malignant neoplasm of broncus and lung are required 14,239.8 chemotherapy courses. The determined cost of 67,000 rubles for the average chemotherapy course per patient takes into account the necessary colony stimulating factors, antiemetic, infusion solutions, etc.; in the case of treatment with erlotinib (the length of the course is 8 months), the cost is 663,408.0 rubles; in the case of treatment with crizotinib (the length of the course is 11 months course), the cost is 2044110.0 rubles. The average cost of drug therapy for one patient with malignant neoplasm of bronchus and lung is 1136155.9 rubles. Conclusion. We determined the pharmacoeconomic dependence of a chemotherapy on the type of malignant neoplasms of bronchus and lung and the main anticancer drug used. The median of the overall survival rate of patients with malignant neoplasms of bronchus and lung was 42 months. The average cost of drug therapy was 27051.3 rubles per month. The median survival rate without therapy is 3 months. Thus, therapy can extend the patient’s life by an average of 39 months. The cost of a month of a saved life is 29132.2 rubles." @default.
• W3020291286 created "2020-05-01" @default.
• W3020291286 creator A5028428218 @default.
• W3020291286 creator A5058024430 @default.
• W3020291286 date "2020-04-24" @default.
• W3020291286 modified "2023-09-27" @default.
• W3020291286 title "The pharmacoeconomic efficacy of chemotherapy for malignant neoplasms of the bronchus and lung" @default.
• W3020291286 doi "https://doi.org/10.17749/2070-4909.2020.13.1.13-22" @default.
• W3020291286 hasPublicationYear "2020" @default.
• W3020291286 type Work @default.
• W3020291286 sameAs 3020291286 @default.
• W3020291286 citedByCount "0" @default.
• W3020291286 crossrefType "journal-article" @default.
• W3020291286 hasAuthorship W3020291286A5028428218 @default.
• W3020291286 hasAuthorship W3020291286A5058024430 @default.
• W3020291286 hasBestOaLocation W30202912862 @default.
• W3020291286 hasConcept C121608353 @default.
• W3020291286 hasConcept C126322002 @default.
• W3020291286 hasConcept C143998085 @default.
• W3020291286 hasConcept C2776256026 @default.
• W3020291286 hasConcept C2776694085 @default.
• W3020291286 hasConcept C2778087573 @default.
• W3020291286 hasConcept C2779438470 @default.
• W3020291286 hasConcept C71924100 @default.
• W3020291286 hasConceptScore W3020291286C121608353 @default.
• W3020291286 hasConceptScore W3020291286C126322002 @default.
• W3020291286 hasConceptScore W3020291286C143998085 @default.
• W3020291286 hasConceptScore W3020291286C2776256026 @default.
• W3020291286 hasConceptScore W3020291286C2776694085 @default.
• W3020291286 hasConceptScore W3020291286C2778087573 @default.
• W3020291286 hasConceptScore W3020291286C2779438470 @default.
• W3020291286 hasConceptScore W3020291286C71924100 @default.
• W3020291286 hasLocation W30202912861 @default.
• W3020291286 hasLocation W30202912862 @default.
• W3020291286 hasOpenAccess W3020291286 @default.
• W3020291286 hasPrimaryLocation W30202912861 @default.
• W3020291286 hasRelatedWork W10145088 @default.
• W3020291286 hasRelatedWork W12336852 @default.
• W3020291286 hasRelatedWork W1671086 @default.
• W3020291286 hasRelatedWork W19759200 @default.
• W3020291286 hasRelatedWork W20592577 @default.
• W3020291286 hasRelatedWork W20825895 @default.
• W3020291286 hasRelatedWork W2785242 @default.
• W3020291286 hasRelatedWork W3586763 @default.
• W3020291286 hasRelatedWork W3852933 @default.
• W3020291286 hasRelatedWork W7661019 @default.
• W3020291286 isParatext "false" @default.
• W3020291286 isRetracted "false" @default.
• W3020291286 magId "3020291286" @default.
• W3020291286 workType "article" @default.